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We report the integrated proviral LTR sequence variation in four patients on highly active antiretroviral therapy (HAART).
Integrated proviral fragments of LTR taken from four time points were PCR amplified from PBMCs and 10 to 12 individual
clones were sequenced for each time point. Intrasample genetic distances and phylogenetic reconstruction of all LTR
sequences demonstrated that 1–2 years of successful HAART did not significantly reduce the genetic repertoire of the
integrated reservoir of HIV-1. © 2001 Academic PressA latent replication-competent integrated HIV-1 reser-
voir persists in resting CD4 T lymphocytes of infected
individuals despite prolonged plasma virus suppression
by successful antiretroviral combination therapy (3, 8,
21). Moreover, a very slow or no reduction in this latently
infected reservoir has been documented after a long
period of plasma virus suppression (7, 11, 16, 17). Low
levels of ongoing viral replication have been correlated
with the slow decay of the HIV-1 latent reservoir (5, 9, 10,
14, 18, 23). The stability of this HIV-1 latent reservoir has
been also associated with the long life of latently in-
fected cells (7, 16, 23).
Since the current antiretroviral agents are ineffective
at eliminating latent forms of HIV-1, this latent viral res-
ervoir remains a major obstacle to virus eradication in
infected individuals (2). Therefore, extensive efforts are
being made to further characterize this virus reservoir. To
investigate whether a long period of successful therapy
affects the genetic composition of this virus reservoir, we
have studied the integrated proviral long terminal repeat
(LTR) sequence variation in four patients on highly active
antiretroviral therapy (HAART) who had had undetectable
levels of HIV-1 RNA for 48 weeks or more.
By measuring over time levels of total and integrated
cell-associated viral DNA we have previously investi-
gated the reservoir of HIV-1 present in peripheral blood
mononuclear cells (PBMCs) of 10 drug-naı¨ve HIV-1-in-
fected patients who started HAART (11). Four patients (B,
C, D, and H) from the former report were selected for this
study. Patients B, D, and H were treated with 3TC, D4T,
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1and ritonavir. Patient C was treated with 3TC, D4T, and
indinavir. Patients B, C, and H were selected on the basis
of their treatment compliance and continued suppres-
sion of plasma HIV-1 RNA (,20 copies/ml). Patient D
was selected because therapy was stopped after 70
weeks of treatment and a plasma viral rebound was
detected at week 72. Patient D resumed therapy (3TC,
D4T, nevirapine, and nelfinavir) at week 93 and showed
again an undetectable plasma viral load at week 108
(Fig. 1). Blood CD4 T cell counts and HIV-1 RNA and DNA
profiles of study individuals are shown in Fig. 1.
To assess the evolution of genetic diversity during
successful therapy, the HIV-1 integrated LTR provirus
sequence variation in the PBMCs from these four indi-
viduals (B, C, D, and H) was analyzed. Integrated proviral
fragments of LTR taken from four time points were PCR
amplified from PBMCs. The study period included a
naı¨ve phase and 1–2 years of therapy (sampling times
are given in Table 1). Population-based sequencing of
the proviral HIV-1 pol region of samples recovered after
108 weeks of therapy did not show amino acid substitu-
tions associated with drug resistance in any of the four
patients studied (data not shown). Diversity in the inte-
grated LTR sequence was quantitatively evaluated for
each patient by computing the intra-time-point genetic
distances derived from individual LTR molecular clones
from the four time points studied (Table 1). The mean
intrasample DNA genetic distances at the beginning of
treatment were 2.3, 2.7, 1.1, and 3.4% for patients B, C, D,
and H, respectively (Table 1). After 48 weeks (32 weeks
for patient C) of therapy no significant reduction in the
intrasample genetic distances was noted (2.2, 2.6, 0.6,
and 3.2%, respectively) compared to the baseline values.
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t2 RAPID COMMUNICATIONFurthermore, samples collected between 48 and 108
weeks of therapy had very similar genetic diversity (2.6,
3.2, 0.9, and 3.1%, respectively) compared with the cor-
responding baseline or 48-week samples (Table 1). Of
note, patient D, who stopped therapy at week 70 and in
which a rebounding plasma viral RNA was detected at
week 72 (Fig. 1), showed a genetic diversity in the former
rebounding viral RNA population (1.7%) similar to that
found in the baseline integrated HIV-1 proviral DNA (Ta-
ble 1). Phylogenetic reconstruction of all LTR sequences
revealed, for each patient, an intermingling of sequences
from the four time points, that is, distinct, temporal clus-
tering of sequences at each time point was not observed
(Fig. 2). This pattern is indicative of absence of genetic
change in this locus during the time period analyzed.
FIG. 1. Summary of CD4 T cell counts and levels of HIV-1 DNA and
after the beginning of the therapy is annotated on the abscissa. CD4 T
per microliter of blood. HIV-1 RNA levels were measured by a quantita
of plasma. Total and integrated HIV-1 DNA copy numbers were calculat
per 106 PBMCs. The times in weeks at which sequencing was perform
he text.Interestingly, the patient D rebounding viral RNA popu-
lation clustered distinctly and was closely associatedwith one proviral DNA clone isolated before the begin-
ning of therapy (Fig. 2). Nevertheless, the low viral ge-
netic diversity and bootstrap proportions (lower than
50–100 replicates) (Fig. 2) observed within patient D did
not allow us to extract any conclusion about the origin of
the rebounding viral RNA detected in this patient as has
been recently shown in other cohorts of patients that
interrupted HAART (1, 22). Taken together, these results
demonstrate that 2 years of successful HAART does not
significantly reduce the genetic repertoire of the inte-
grated reservoir of HIV-1 DNA present in latently infected
CD4 T cells.
Several recent reports have stressed the stability of
the HIV-1 latent reservoir after successful combination
therapy (7, 11, 16, 17, 18). Here we show that accompa-
ssociated RNA for each of the four patients (B, C, D, and H). The time
nts were measured by flow-activated cytometric assay and expressed
erse transcription-PCR assay (Roche) and are expressed per milliliter
uantitative nested PCR as described previously (11) and are expressed
indicated in Table 1. Specific antiretroviral therapies are described invirion-a
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FIG. 2. Neighbor-joining phylogram of integrated proviral LTR sequ
patient D plasma HIV-1 RNA population is also shown (green circles). P
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four patients was generated by using the Kimura two-parameter distan
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tamination. Phylogenetic reconstruction of all viral sequences from the
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stability of the HIV-1 latent reservoir.
Our findings indicate that the current antiretroviral
therapies are ineffective at reducing the HIV-1 latent
genetic repertoire. Therefore, treatment with suppressive
protocols that include immune stimulation or structured
interruption of therapy have to take into account that the
virus population that will emerge may contain their entire
repertoire of variants (drug-resistant mutants or syncyti-
um-inducing viruses, etc.) present before the beginning
of the therapy.
Materials and Methods. Patients. Four drug-naı¨ve HIV-
1-seropositive patients who started a triple combination
therapy were selected for this study. Patients B, D, and H
were treated with 3TC, D4T, and ritonavir. Patient C was
treated with 3TC, D4T, and indinavir (11). Blood CD4 T
cell counts and HIV-1 RNA and DNA levels are shown in
Fig. 1. Plasma HIV-1 RNA levels were measured by the
Amplicor monitor assay (Roche). Total and integrated
HIV-1 DNA quantification was performed by end-point
limiting dilution, as described previously (11).
Recovery and Analysis of DNA and RNA Sequences.
We tracked the HIV-1 integrated provirus sequence
variation in the PBMCs obtained from sequential blood
samples from three patients (B, C, and H) that were
TABLE 1
Mean Intrasample Time Point Genetic Distances in the HIV-1
ntegrated Proviral LTR Population before, at Start of, and during
herapy
Patient
Sampling time
(weeks before
or after therapy)
No. of
clones
analyzed
Mean DNA
distance
% 6 SD
P value
(Wilcoxon signed
rank test)a
B 295 12 2.0 6 0.9 0.496
0 12 2.3 6 1.5
48 12 2.2 6 1.1 0.845
108 11 2.6 6 1.2 0.186
C 256 10 2.1 6 1.4 0.026
0 10 2.7 6 1.2
32 11 2.6 6 1.3 0.704
48 10 3.2 6 1.1 0.069
D 216 11 0.6 6 0.4 ,0.0001
0 12 1.1 6 1.0
48 11 0.6 6 0.4 0.007
72 12 0.9 6 0.5 0.152
72 (RNA)b 10 1.7 6 0.7b 0.470
H 260 11 1.5 6 0.8 ,0.0001
0 10 3.4 6 2.1
48 10 3.2 6 1.6 0.725
72 10 3.1 6 1.7 0.247
a Wilcoxon signed rank test compares intra-time-point DNA distance
istributions to those obtained at week 0.
b Mean intrasample RNA distance of the 72-week patient D plasma
HIV-1 RNA.able to maintain undetectable levels of plasma HIV-1
RNA (below 20 copies/ml) (Fig. 1) for 108 weeks and
T
Ffrom another patient (D) who stopped treatment after
70 weeks of therapy. Genomic PBMC DNA purification
and PCR amplification were performed as described
previously (11). To specifically amplify integrated DNA
we used an oligonucleotide (Alu-LTR 59) designed to
amplify cellular Alu repeat sequences (19). Sequences
of the oligonucleotides used are Alu-LTR 59, 59-TC-
CCAGCTACTCGGGAGGCTGAGG-39 (nt 164 to 187 of
the Alu consensus sequence (12), and Alu-LTR 39,
59-AGGCAAGCTTTATTGAGGTTAAGC-39 (HIV-1 HXB2
positions 516 to 540). For the nested PCR oligonucle-
otides NI-2 59, 59-CACACACAAGGCTACTTCCCT-39
(HIV-1 HXB2 positions 57 to 77), and NI-2 39, 59-GC-
CACTCCCCIGTCCCGCCC-39 (HIV-1 HXB2 positions
389 to 408), described by Chun et al. (3), were used.
End-point dilution of PBMC DNA was performed be-
fore nested PCR to make products derived from a
single provirus. For each sample at least 10 amplicons
were directly sequenced with a 310 automated se-
quencer and dRhodamine chain terminator chemistry
(Applied Biosystems). The 72-week patient D plasma
sample was processed for RNA extraction as previ-
ously described (14). The viral RNA was retrotrans-
cribed into cDNA with oligonucleotide NI-2 39. cDNA
was PCR amplified with oligonucleotides NI-2 59 and
NI-2 39, followed by a second round of amplification
with oligonucleotides NI-3 59, 59-TGGCAGAACTACA-
CACCAGG-39 (HIV-1 HXB2 positions 81 to 100), and
NI-3 39, 59-GAAAGTCCCCAGCGGAAAGTCCC-39 (HIV-1
HXB2 positions 350 to 372). As for the PBMC samples,
end-point dilution of the cDNA was performed before
nested PCR. The sequencing oligonucleotide was NI-3
59. Sequences were aligned using CLUSTAL W (20).
Pairwise nucleotide distances (excluding gaps in the
pairwise alignment) were calculated with the Kimura
two-parameter model of evolution with a transition/
transversion ratio of 2 as implemented in WET (4).
Phylogenetic reconstructions were generated by using
the neighbor-joining method included in the PHYLIP
software package (6). The distribution of nucleotide
distances for each patient time point was subjected to
nonparametric statistical treatment by using the Wil-
coxon signed rank test included in the SPSS version
7.5 software package.
Nucleotide Sequence Accession Numbers. The nucle-
otide sequence data reported in this paper have been
submitted to the GenBank database under Accession
No. AF294033 to AF294223.
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